Taletrectinib's Sustained Efficacy in Advanced ROS1-Positive NSCLC
Published: | Updated:
New data highlightstaletrectinib's impressive efficacy and safety in treating ROS1-positive non–small cell lung cancer, offering hope for patients.
Geoffrey Liu, MD
Geoffrey Liu, MD, is a medical oncologist at Princess Margaret Cancer Center, University of Toronto.
Articles by Geoffrey Liu, MD
Latest Updated Articles
Taletrectinib's Sustained Efficacy in Advanced ROS1-Positive NSCLCPublished: September 8th 2025 | Updated: October 24th 2025